APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration

Overview of attention for article published in British Journal of Ophthalmology, June 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (74th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 3 X users

patent: 3 patents

Readers on

mendeley: 34 Mendeley

So far, Altmetric has seen 5 X posts from 3 X users, with an upper bound of 4,006 followers.

APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration @BMJ_Ophth | #ECM https://t.co/vzl4mb6m2w

APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration https://t.co/WdIYtaJYDf #bmj #oftalmologia #ophthalmology

Ophthopedia Update: APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration https://t.co/MdH9Tms4ba #Ophthalmology #Ophthotwitter #BJO https://t.co/d0y8Yf…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.